GPRC5D
GPRC5D is a second myeloma target used when BCMA-directed drugs stop working. This dossier gathers the 1 product (1 approved), 1 trial, 0 pathways and 1 resistance route in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
GPRC5D is an orphan class C GPCR.
- Multiple myeloma
Elsewhere: identifiers and databases
Built from HGNC, Ensembl, UniProt and ChEMBL idsHow common it is, by cancer
Full matrix →| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Multiple myeloma | 60-80% | High expression by IHC/RNA | Expression correlates with high risk | Wikipedia |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
Products by modality and phase
Browse products →| Modality | Approved |
|---|---|
| T-cell engager 1 |
Trials
Evidence ranking →| Trial | Phase | Status | Setting | Result | Products |
|---|---|---|---|---|---|
| MonumenTAL-1 NCT04634552 | 1/2 | Positive | Relapsed/refractory myeloma after ≥3 lines: talquetamab (weekly or biweekly) | ORR ~73%. |
Resistance routes that involve this target
Unaddressed routes →Deletion or mutation removes or alters the epitope; more common after bispecifics than CAR-T.
- Switch to GPRC5D-directed therapy (talquetamab, GPRC5D CAR-T) or FcRH5
Pathways where it is a node
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics and assays
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Ideas and companies
Key papers and the live literature
Preprints →- MagnetisMM-3: elranatamab, a second BCMA bispecific, with a switch to fortnightly dosing after response · Nature Medicine 2023
Query for this target: (TITLE:"GPRC5D" OR ABSTRACT:"GPRC5D") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about GPRC5D, not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/gprc5d.json. Licence CC BY 4.0.